MuReva Phototherapy presented data from a pilot trial incorporating the us a the company’s LED=based intraoral Photobiomodulation (PBM) device for daily use in head and neck cancer patients undergoing radiation therapy during the 2023 Annual Meeting of the Multinational Association Of Supportive Care In Cancer (MASCC) held June 22nd to 24th in Nara, Japan. 

The results from the pilot study were encouraging with a reduction in the severity of oral mucositis and for the the retention of salivary flow and swallowing ability. Treatment with the PBM device was well tolerated (97% of treatments were completed in full), safe with no device-related adverse events and 97% of subjects being satisfied with their treatment experience.

Click on the image below to enlarge.